Acute myeloid leukemia Trials in Commack, United States
Conditions / Acute myeloid leukemia / Commack, United States
Research into Acute myeloid leukemia spans multiple therapeutic approaches and trial phases.
13 total trials for this combination
Showing top 10 of 13 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05554406 | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | RECRUITING | — |
| NCT03530683 | A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma | TERMINATED | PHASE1 |
| NCT06672146 | Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | RECRUITING | — |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | RECRUITING | PHASE1/PHASE2 |
| NCT06017258 | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | RECRUITING | PHASE1 |
| NCT05554393 | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | RECRUITING | — |
| NCT06484062 | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | RECRUITING | — |
| NCT06317649 | Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | RECRUITING | — |
| NCT05564390 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | RECRUITING | — |
| NCT05024994 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | COMPLETED | PHASE2 |